Dehydration News and Research

Latest Dehydration News and Research

Mass vaccination strategy could prevent future cholera epidemics in Zimbabwe

Mathematical models analyzing how a cholera outbreak spread in Zimbabwe are providing new insights into the most effective vaccination strategies for preventing future cholera epidemics, according to University of Florida researchers.

3 Jun 2011

WGO to focus on diarrheal disease prevention, management during World Digestive Health Day

Diarrheal disease, a common gastrointestinal problem with potentially fatal implications in the developing world is the focus of World Digestive Health Day on May 29. Infections that cause diarrhea are serious public health challenges, both in the United States and globally.

27 May 2011

Cattle plague – rinderpest, eradicated for good

As welcome news, world farm monitors on Wednesday declared a cattle-killing virus that has been a curse through the ages as eradicated. This is the first time an animal disease has been eradicated in human history. The global watchdog for farm-animal trade approved a report certifying that the last 14 countries of the world were free of rinderpest, also called cattle plague.

26 May 2011

Tips for building strong and healthy bones

Most of us think of our bone structure as a solid, static mass that is hard and unchanging. The fact is our skeletal structure is replaced approximately every ten years.

26 May 2011

Automated microfluidic device can monitor hematopoietic stem cells

A Canadian research team has developed an automated microfluidic cell culture platform to monitor the growth, survival and responses of hundreds of hematopoietic stem cells at the single cell level.

23 May 2011

ViroPharma commences VP 20621 Phase 2 study for prevention of recurrent Clostridium difficile infection

ViroPharma Incorporated today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI.

20 May 2011

GATTEX Phase 3 study results in adult short bowel syndrome presented at DDW 2011

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that GATTEX, a novel, recombinant analog of human glucagon-like peptide 2, was found to effectively and safely reduce parenteral support volume in adult short bowel syndrome-intestinal failure patients.

11 May 2011

Allos, Mundipharma enter strategic collaboration to co-develop FOLOTYN

Allos Therapeutics, Inc. and Mundipharma International Corporation Limited today jointly announced that the companies have entered into a strategic collaboration agreement to co-develop FOLOTYN (pralatrexate injection).

11 May 2011

Study confirms LcS-fermented milk reduces fever linked with acute norovirus gastroenteritis

The Laboratory Department for Probiotics Research at the Juntendo University Graduate School of Medicine studied supplementation of probiotic fermented milk containing Lactobacillus casei strain Shirota in elderly individuals living at a nursing home and confirmed reduced fever associated with acute norovirus gastroenteritis.

10 May 2011

Millennium presents VELCADE Phase III trial data in multiple myeloma at IMW meeting

Millennium: The Takeda Oncology Company today reported the presentation of results of a randomized Phase III trial that investigated the effect of consolidation with single-agent VELCADE for Injection in newly diagnosed multiple myeloma patients after autologous stem cell transplant.

7 May 2011

Millennium presents three studies in relapsed multiple myeloma at IMW meeting

Millennium: The Takeda Oncology Company today reported results from three studies in relapsed multiple myeloma. Two of the studies examined the use of VELCADE for Injection; the third study presents clinical data on MLN9708, the first investigational oral proteasome inhibitor.

6 May 2011

Millennium submits two VELCADE sNDAs to FDA

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that it has submitted two supplemental new drug applications (sNDAs) for VELCADE® (bortezomib) for Injection to the U.S. Food and Drug Administration. The first application seeks to add a subcutaneous route of administration for VELCADE. The second application is for the use of VELCADE in combination with rituximab in patients with relapsed follicular non-Hodgkin lymphoma (NHL).

26 Apr 2011

Klotho hormone can protect kidney from renal fibrosis

A natural hormone known to inhibit aging can also protect kidneys against renal fibrosis, UT Southwestern Medical Center researchers have demonstrated.

15 Apr 2011

Elevated levels of sodium limit body's natural responses to stress

All those salty snacks available at the local tavern might be doing more than increasing your thirst: They could also play a role in suppressing social anxiety.

6 Apr 2011

Sickle cell trait can cause sudden death in young African-American athletes

The sickle cell trait could be a cause-albeit rare-of sudden death in young African-American competitive athletes, most commonly during football training, according to a scientific poster that will be presented at the American College of Cardiology Scientific Sessions, April 1-3, in New Orleans.

4 Apr 2011

CorMedix reports encouraging interim results from CRMD001 phase II study in Contrast Induced Acute Kidney Injury

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced its interim analysis and clinical update for CRMD001.

1 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

Amgen announced today that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in March by the Committee For Medicinal Products for Human Use (CHMP) for the use of Vectibix in combination with chemotherapy for patients with wild-type KRAS metastatic colorectal cancer (mCRC).

31 Mar 2011

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

Amgen has received notice that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for Amgen's application to extend the marketing authorization in Europe for Vectibix® (panitumumab) to include combination with chemotherapy for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC).

18 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Dehydration News and Research

Latest Dehydration News and Research

Mass vaccination strategy could prevent future cholera epidemics in Zimbabwe

WGO to focus on diarrheal disease prevention, management during World Digestive Health Day

Cattle plague – rinderpest, eradicated for good

Tips for building strong and healthy bones

Automated microfluidic device can monitor hematopoietic stem cells

ViroPharma commences VP 20621 Phase 2 study for prevention of recurrent Clostridium difficile infection

GATTEX Phase 3 study results in adult short bowel syndrome presented at DDW 2011

Allos, Mundipharma enter strategic collaboration to co-develop FOLOTYN

Study confirms LcS-fermented milk reduces fever linked with acute norovirus gastroenteritis

Millennium presents VELCADE Phase III trial data in multiple myeloma at IMW meeting

Millennium presents three studies in relapsed multiple myeloma at IMW meeting

Millennium submits two VELCADE sNDAs to FDA

Klotho hormone can protect kidney from renal fibrosis

Elevated levels of sodium limit body's natural responses to stress

Sickle cell trait can cause sudden death in young African-American athletes

CorMedix reports encouraging interim results from CRMD001 phase II study in Contrast Induced Acute Kidney Injury

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Dehydration News and Research

Latest Dehydration News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in